Moreover, Kondo et al. have suggested that the dopamine agonist therapies that are more commonly used in EOPD might reduce dopamine transporter (DAT) loss during PD disease progression (Kondo, 2002). This evidence concerns the gene SLC6A3 and Parkinson disease.